Connect with us

Hi, what are you looking for?


Pfizer targets at least 2 billion COVID-19 vaccine doses this year, sees $15 billion in 2021 from the shots

Pfizer also said it expects there could be a long-lasting need for COVID-19 vaccines, to combat new virus variants that emerge and to boost peoples’ waning immune responses. Image via Reuters/Dado Ruvic/Illustration/File Photo

Pfizer Inc. said on Tuesday it expects to generate $15 billion, or about a quarter of its total revenue this year, from sales of its coronavirus disease 2019 (COVID-19) vaccine co-developed with German partner BioNTech SE. 

Sales from the vaccine—on track to be the drugmaker’s top product this year—could top $15 billion if the company signs more supply contracts, it said. 

Pfizer aims to make two billion doses of the COVID-19 vaccine in 2021. Pfizer Chief Executive Albert Bourla said in an interview that the company wanted to be conservative in its target and is working on numerous initiatives to exceed that output. 

“We’ve increased the batches we run per week, we’ve doubled the output—the yield per batch—we’ve dramatically improved our success rates, we’ve made process improvements to the assembly lines,” Chief Financial Officer Frank D’Amelio said in the interview. 

“All these things are things we’re continuing to examine to see what else we can do to try to produce more doses faster,” he added. 

Pfizer also said it expects there could be a long-lasting need for COVID-19 vaccines, to combat new virus variants that emerge and to boost peoples’ waning immune responses. 

The company is launching a study to determine whether a third dose of the COVID-19 vaccine, administered 6-to-12 months after the initial shots, can extend and improve efficacy with more contagious variants circulating in communities around the world. The Pfizer/BioNTech vaccine is currently administered as two doses three weeks apart. 

Chief Scientific Officer Mikael Dolsten said he believes mRNA vaccines like Pfizer’s generate a strong enough immune response to repel the currently circulating variants, and that a booster, rather than a redesigned vaccine, is the right approach for now. 

Citi analyst Andrew Baum said he was optimistic that revenue contributions from the vaccine could be sustainable beyond 2021. 

Pfizer expects to supply 200 million doses to the US government by the end of May. 

To achieve the goal, it will have to deliver an average of around 10 million doses per week, more than double the rate Pfizer and BioNTech delivered to the United States through the end of January, according to Reuters calculations. 

The vaccine, which uses synthetic messenger RNA (mRNA) to prompt an immune response against the virus, was the first shot to be authorized for emergency use in the United States, marking the first regulatory nod for the new technology. 

mRNA vaccines and COVID-19 could prove transformative for Pfizer, which is already one of the world’s largest drugmakers, Mr. Bourla said. A potential flu vaccine based on the technology could hit the market by 2025, executives said on a conference call. 

Pfizer forecast 2021 sales between $59.4 billion and $61.4 billion. The company raised both ends of its full-year adjusted profit forecast by 10 cents and now expects to earn $3.10 to $3.20 per share. — Manas Mishra and Michael Erman/Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!



By Keisha B. Ta-asan, Reporter THE NATIONAL Government’s (NG) outstanding debt hit a record-high P13.75 trillion as of end-February as domestic borrowings increased, the...


STATE SPENDING on infrastructure rose by 13.4% in 2022, as the government ramped up public works and transportation-related projects. According to the Department of...


BUSINESSES NOW have a more optimistic economic outlook this year, amid a return to pre-pandemic normalcy and increased consumer demand, a survey by the...


SEVERAL former government officials are opposing the plan to merge Landbank of the Philippines (LANDBANK) with the Development Bank of the Philippines (DBP), saying...


MONDE NISSIN CORP. suffered a net loss of P13.03 billion in 2022, a reversal of its P3.12-billion net income a year earlier, due to...


MGEN RENEWABLE Energy, Inc. (MGreen) is keen to expand its 68-megawatt-alternating current (MWac) solar plant project with Vena Energy in Ilocos Norte. “This is...

You May Also Like


Browsing history makes referring to sites and pages you’ve visited in the past seamless. It’ll help you recall what page you checked out on...


The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...


Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...


Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.